Mr. Shaun Flanagan:

On the timeline, it is important to flag that horizon scanning in the pharmaceutical field is a challenging enough predictive process. I would not call it a science. It can be hard to figure out what medicine is going to be on the market in two or three years' time. For example, it was expected that a medicine used in the treatment of Alzheimer's disease would be close to market at this stage, but it has had setbacks in the US. It does not look like it will get to the European market in the next year. This time last year, we expected that the medicine would be close to market now. Things like that happen, so it can be difficult to predict. The BeNeLuxA initiative is spending a significant amount of time and resources on trying to make the horizon scanning process more robust, so that we can better predict what our demands or needs are, and what our ask of the Oireachtas will be in terms of what funding we need.